Integra LifeSciences (IART) announced the FDA 510(k) clearance for use of its Cusa Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Private Markets: Anthropic projects $70B in revenue in 2028
- Integra LifeSciences price target lowered to $13 from $15 at Truist
- Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements
- Integra LifeSciences price target raised to $13 from $12 at JPMorgan
- Integra LifeSciences price target lowered to $11 from $12 at Citi